IDOL enzyme - new Alzheimer's drug target reduces amyloid plaques and lowers APOE in neurons (Indiana University, Alzheimer's & Dementia)

Indiana University School of Medicine researchers identified a brain enzyme called IDOL whose removal from neurons sharply cuts amyloid plaques and lowers APOE, the protein whose APOE4 variant is the strongest genetic risk factor for late-onset Alzheimer's. Unlike current FDA-app

Indiana University School of Medicine researchers identified a brain enzyme called IDOL as a new drug target. In animal models, removing IDOL from neurons sharply cut amyloid plaques and lowered APOE, the protein whose APOE4 variant is the strongest genetic risk factor for late-onset Alzheimer's. Current drugs like lecanemab and donanemab only clear existing plaques. Published in Alzheimer's and Dementia.

Show more